1268 related articles for article (PubMed ID: 8988460)
1. The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research.
Magyar K; Szende B; Lengyel J; Tekes K
J Neural Transm Suppl; 1996; 48():29-43. PubMed ID: 8988460
[TBL] [Abstract][Full Text] [Related]
2. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
Magyar K; Szende B
Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
[TBL] [Abstract][Full Text] [Related]
3. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective actions of selegiline.
Ebadi M; Sharma S; Shavali S; El Refaey H
J Neurosci Res; 2002 Feb; 67(3):285-9. PubMed ID: 11813232
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective and neuronal rescue effects of selegiline: review.
Magyar K; Haberle D
Neurobiology (Bp); 1999; 7(2):175-90. PubMed ID: 10591051
[TBL] [Abstract][Full Text] [Related]
6. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
Knoll J
Pharmacol Toxicol; 1998 Feb; 82(2):57-66. PubMed ID: 9498233
[TBL] [Abstract][Full Text] [Related]
7. The molecular pharmacology of L-deprenyl.
Gerlach M; Riederer P; Youdim MB
Eur J Pharmacol; 1992 Jun; 226(2):97-108. PubMed ID: 1639115
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
9. Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.
Olanow CW
J Neural Transm Suppl; 1996; 48():75-84. PubMed ID: 8988463
[TBL] [Abstract][Full Text] [Related]
10. R-deprenyl: pharmacological spectrum of its activity.
Magyar K; Szende B; Jenei V; Tábi T; Pálfi M; Szöko E
Neurochem Res; 2010 Dec; 35(12):1922-32. PubMed ID: 20725780
[TBL] [Abstract][Full Text] [Related]
11. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase.
Tatton WG; Wadia JS; Ju WY; Chalmers-Redman RM; Tatton NA
J Neural Transm Suppl; 1996; 48():45-59. PubMed ID: 8988461
[TBL] [Abstract][Full Text] [Related]
12. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.
Fuller RW; Hemrick-Luecke SK; Kindt MV; Heikkila RE
Life Sci; 1988; 42(3):263-71. PubMed ID: 3121972
[TBL] [Abstract][Full Text] [Related]
13. Effect of MAO-B inhibitors on MPP+ toxicity in Vivo.
Wu RM; Chen RC; Chiueh CC
Ann N Y Acad Sci; 2000; 899():255-61. PubMed ID: 10863544
[TBL] [Abstract][Full Text] [Related]
14. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
Knoll J
Biomed Pharmacother; 1995; 49(4):187-95. PubMed ID: 7669938
[TBL] [Abstract][Full Text] [Related]
15. The neuroprotective and neuronal rescue effects of (-)-deprenyl.
Magyar K; Szende B; Lengyel J; Tarczali J; Szatmáry I
J Neural Transm Suppl; 1998; 52():109-23. PubMed ID: 9564614
[TBL] [Abstract][Full Text] [Related]
16. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.
Szökő É; Tábi T; Riederer P; Vécsei L; Magyar K
J Neural Transm (Vienna); 2018 Nov; 125(11):1735-1749. PubMed ID: 29417334
[TBL] [Abstract][Full Text] [Related]
18. Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B.
Finnegan KT; Skratt JJ; Irwin I; DeLanney LE; Langston JW
Eur J Pharmacol; 1990 Aug; 184(1):119-26. PubMed ID: 2120076
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
20. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.
Klegeris A; McGeer PL
Exp Neurol; 2000 Dec; 166(2):458-64. PubMed ID: 11085911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
